RNS Number : 4565U
Ondine Biomedical Inc.
28 June 2024
 

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Result of AGM and voting results

Ondine Biomedical (AIM: OBI) announces that at its Annual General Meeting held on 28 June 2024 all resolutions were duly passed.

The voting results of the AGM were as follows:

 

In Favor

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1. Election of Directors






Carolyn Cross

191,380,245

100.00

0

0.00

0

Nicolas G. Loebel

191,380,245

100.00

0

0.00

0

Jean Charest

190,741,872

99.67

0

0.00

638,373

Jean Duvall

190,741,872

99.67

0

0.00

638,373

Junaid Bajwa

190,741,872

99.67

0

0.00

638,373

Michael Farrar

190,741,872

99.67

0

0.00

638,373

Craig Tooman

190,741,872

99.67

0

0.00

638,373

2. Appointment of Auditors

191,380,245

100.00

0

0.00

0

 

Enquiries:

​

Ondine Biomedical Inc.       

 

Carolyn Cross, CEO 

+001 (604) 665 0555

 

 

Singer Capital Markets
(Nominated Adviser and Joint Broker)

 

Aubrey Powell, Sam Butcher, Jalini Kalaravy

+44 (0)20 7496 3000

 

 

RBC Capital Markets (Joint Broker)

 

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000


 

Vane Percy & Roberts (Media Contact)


Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe, the UK-CA mark, and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEAKKPADNLEFA
Ondine Biomedical (LSE:OBI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Ondine Biomedical.
Ondine Biomedical (LSE:OBI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Ondine Biomedical.